Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Diagnosis and Treatment of Myxoid Liposarcomas: Histology Matters.

Abaricia S, Hirbe AC.

Curr Treat Options Oncol. 2018 Oct 25;19(12):64. doi: 10.1007/s11864-018-0590-5. Review.

PMID:
30362022
2.

Aberrant ATRX protein expression is associated with poor overall survival in NF1-MPNST.

Lu HC, Eulo V, Apicelli AJ, Pekmezci M, Tao Y, Luo J, Hirbe AC, Dahiya S.

Oncotarget. 2018 May 1;9(33):23018-23028. doi: 10.18632/oncotarget.25195. eCollection 2018 May 1.

3.

β-III-spectrin immunohistochemistry as a potential diagnostic tool with high sensitivity for malignant peripheral nerve sheath tumors.

Hirbe AC, Zhang X, Dahiya S, Godec A, Chrisinger J, Tao Y, Luo J, Gutmann DH.

Neuro Oncol. 2018 May 18;20(6):858-860. doi: 10.1093/neuonc/noy038. No abstract available.

PMID:
29596596
4.

A Phase II Study of Tumor Ablation in Patients with Metastatic Sarcoma Stable on Chemotherapy.

Hirbe AC, Jennings J, Saad N, Giardina JD, Tao Y, Luo J, Berry S, Toeniskoetter J, Van Tine BA.

Oncologist. 2018 Jul;23(7):760-e76. doi: 10.1634/theoncologist.2017-0536. Epub 2018 Feb 27.

5.

Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review.

Oppelt PJ, Hirbe AC, Van Tine BA.

J Gastrointest Oncol. 2017 Jun;8(3):466-473. doi: 10.21037/jgo.2016.09.15. Review.

6.

Neoadjuvant Ifosfamide and Epirubicin in the Treatment of Malignant Peripheral Nerve Sheath Tumors.

Hirbe AC, Cosper PF, Dahiya S, Van Tine BA.

Sarcoma. 2017;2017:3761292. doi: 10.1155/2017/3761292. Epub 2017 May 4.

7.

Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.

Hirbe AC, Kaushal M, Sharma MK, Dahiya S, Pekmezci M, Perry A, Gutmann DH.

Cancer. 2017 Apr 1;123(7):1194-1201. doi: 10.1002/cncr.30455. Epub 2016 Nov 22.

8.

Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor Nf1 gene loss to promote malignant peripheral nerve sheath tumor formation.

Hirbe AC, Dahiya S, Friedmann-Morvinski D, Verma IM, Clapp DW, Gutmann DH.

Oncotarget. 2016 Feb 16;7(7):7403-14. doi: 10.18632/oncotarget.7232.

9.

Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma.

Hirbe AC, Dahiya S, Miller CA, Li T, Fulton RS, Zhang X, McDonald S, DeSchryver K, Duncavage EJ, Walrath J, Reilly KM, Abel HJ, Pekmezci M, Perry A, Ley TJ, Gutmann DH.

Clin Cancer Res. 2015 Sep 15;21(18):4201-11. doi: 10.1158/1078-0432.CCR-14-3049. Epub 2015 Apr 29.

10.

A multidisciplinary approach in neurofibromatosis 1--authors' reply.

Epstein JA, Ingram DA Jr, Hirbe AC, Gutmann DH.

Lancet Neurol. 2015 Jan;14(1):30-1. doi: 10.1016/S1474-4422(14)70298-4. No abstract available.

PMID:
25496893
11.

Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas.

Pekmezci M, Reuss DE, Hirbe AC, Dahiya S, Gutmann DH, von Deimling A, Horvai AE, Perry A.

Mod Pathol. 2015 Feb;28(2):187-200. doi: 10.1038/modpathol.2014.109. Epub 2014 Sep 5.

12.

Neurofibromatosis type 1: a multidisciplinary approach to care.

Hirbe AC, Gutmann DH.

Lancet Neurol. 2014 Aug;13(8):834-43. doi: 10.1016/S1474-4422(14)70063-8. Review.

13.

BRAFV600E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors.

Hirbe AC, Pekmezci M, Dahiya S, Apicelli AJ, Van Tine BA, Perry A, Gutmann DH.

Neuro Oncol. 2014 Mar;16(3):466-7. doi: 10.1093/neuonc/not248. Epub 2013 Dec 22. No abstract available.

14.

Novel pathways and molecular targets for the treatment of sarcoma.

Frith AE, Hirbe AC, Van Tine BA.

Curr Oncol Rep. 2013 Aug;15(4):378-85. doi: 10.1007/s11912-013-0319-3. Review.

PMID:
23661264
15.

The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling.

Su X, Floyd DH, Hughes A, Xiang J, Schneider JG, Uluckan O, Heller E, Deng H, Zou W, Craft CS, Wu K, Hirbe AC, Grabowska D, Eagleton MC, Townsley S, Collins L, Piwnica-Worms D, Steinberg TH, Novack DV, Conley PB, Hurchla MA, Rogers M, Weilbaecher KN.

J Clin Invest. 2012 Oct;122(10):3579-92. doi: 10.1172/JCI38576. Epub 2012 Sep 17.

16.

CD8+ T cells regulate bone tumor burden independent of osteoclast resorption.

Zhang K, Kim S, Cremasco V, Hirbe AC, Collins L, Piwnica-Worms D, Novack DV, Weilbaecher K, Faccio R.

Cancer Res. 2011 Jul 15;71(14):4799-808. doi: 10.1158/0008-5472.CAN-10-3922. Epub 2011 May 20. Erratum in: Cancer Res. 2012 Jan 15;72(2):568.

17.

The CXCR4/SDF-1 chemokine axis: a potential therapeutic target for bone metastases?

Hirbe AC, Morgan EA, Weilbaecher KN.

Curr Pharm Des. 2010;16(11):1284-90. Review.

PMID:
20166978
18.

The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts.

Hirbe AC, Roelofs AJ, Floyd DH, Deng H, Becker SN, Lanigan LG, Apicelli AJ, Xu Z, Prior JL, Eagleton MC, Piwnica-Worms D, Rogers MJ, Weilbaecher K.

Bone. 2009 May;44(5):908-16. doi: 10.1016/j.bone.2009.01.010. Epub 2009 Jan 23.

19.

RelB is the NF-kappaB subunit downstream of NIK responsible for osteoclast differentiation.

Vaira S, Johnson T, Hirbe AC, Alhawagri M, Anwisye I, Sammut B, O'Neal J, Zou W, Weilbaecher KN, Faccio R, Novack DV.

Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3897-902. doi: 10.1073/pnas.0708576105. Epub 2008 Mar 5.

20.

APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice.

Uluçkan O, Eagleton MC, Floyd DH, Morgan EA, Hirbe AC, Kramer M, Dowland N, Prior JL, Piwnica-Worms D, Jeong SS, Chen R, Weilbaecher K.

J Cell Biochem. 2008 Jul 1;104(4):1311-23. doi: 10.1002/jcb.21709.

21.

A non-tumor suppressor role for basal p19ARF in maintaining nucleolar structure and function.

Apicelli AJ, Maggi LB Jr, Hirbe AC, Miceli AP, Olanich ME, Schulte-Winkeler CL, Saporita AJ, Kuchenreuther M, Sanchez J, Weilbaecher K, Weber JD.

Mol Cell Biol. 2008 Feb;28(3):1068-80. Epub 2007 Dec 10.

22.

Disruption of CXCR4 enhances osteoclastogenesis and tumor growth in bone.

Hirbe AC, Rubin J, Uluçkan O, Morgan EA, Eagleton MC, Prior JL, Piwnica-Worms D, Weilbaecher KN.

Proc Natl Acad Sci U S A. 2007 Aug 28;104(35):14062-7. Epub 2007 Aug 22.

23.

Granulocyte colony-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner.

Hirbe AC, Uluçkan O, Morgan EA, Eagleton MC, Prior JL, Piwnica-Worms D, Trinkaus K, Apicelli A, Weilbaecher K.

Blood. 2007 Apr 15;109(8):3424-31. Epub 2006 Dec 27.

24.

Skeletal complications of breast cancer therapies.

Hirbe A, Morgan EA, Uluçkan O, Weilbaecher K.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6309s-6314s. Review.

25.

MRI detection of early bone metastases in b16 mouse melanoma models.

Gauvain KM, Garbow JR, Song SK, Hirbe AC, Weilbaecher K.

Clin Exp Metastasis. 2005;22(5):403-11.

26.

HTLV-1 Tax transgenic mice develop spontaneous osteolytic bone metastases prevented by osteoclast inhibition.

Gao L, Deng H, Zhao H, Hirbe A, Harding J, Ratner L, Weilbaecher K.

Blood. 2005 Dec 15;106(13):4294-302. Epub 2005 Aug 23.

27.

Functional analysis of neurofibromatosis 2 (NF2) missense mutations.

Gutmann DH, Hirbe AC, Haipek CA.

Hum Mol Genet. 2001 Jul 1;10(14):1519-29.

PMID:
11448944
28.

The protein 4.1 tumor suppressor, DAL-1, impairs cell motility, but regulates proliferation in a cell-type-specific fashion.

Gutmann DH, Hirbe AC, Huang ZY, Haipek CA.

Neurobiol Dis. 2001 Apr;8(2):266-78.

PMID:
11300722
29.

Developmental regulation of a neuron-specific neurofibromatosis 1 isoform.

Gutmann DH, Zhang Y, Hirbe A.

Ann Neurol. 1999 Nov;46(5):777-82.

PMID:
10553997
30.

Molecular analysis of malignant triton tumors.

Strauss BL, Gutmann DH, Dehner LP, Hirbe A, Zhu X, Marley EF, Liapis H.

Hum Pathol. 1999 Aug;30(8):984-8.

PMID:
10452514

Supplemental Content

Support Center